13551-76-3

Upstream product

• 89-25-8 edaravone 
• 1131-17-5 5-chloro-3-methyl-1-phenyl-1H-pyrazole 

Downstream Products

• 78777-67-0 3-methyl-4-nitro-1-phenyl-1H-pyrazole-5-carbonitrile 
• 1608125-54-7 3-methyl-5-(3-methyl-1-phenyl-1H-pyrazol-5-yloxy)-4-nitro-1-phenyl-1H-pyrazole 
• 1608125-55-8 3-methyl-5-(3-methyl-1-phenyl-1H-pyrazol-5-yloxy)-1-phenyl-1H-pyrazol-4-amine 
• 136389-77-0 (5-methyl-4-nitro-2-phenyl-2H-pyrazol-3-yl)-(3-methylphenyl)amine 
• 136389-76-9 (5-methyl-4-nitro-2-phenyl-2H-pyrazol-3-yl)-(4-methylphenyl)amine 
• 1381770-80-4 3-methyl-5-(3-methyl-5-phenyl-1H-pyrazol-1-yl)-1-phenyl-1H-pyrazol-4-amine 

Relevant academic research and scientific papers

Structure-activity relationships of pyrazole derivatives as potential therapeutics for immune thrombocytopenias

Idiopathic or immune thrombocytopenia (ITP) is a serious clinical disorder involving the destruction of platelets by macrophages. Small molecule therapeutics are highly sought after to ease the burden on current therapies derived from human sources. Earlier, we discovered that dimers of five-membered heterocycles exhibited potential to inhibit phagocytosis of human RBCs by macrophages. Here, we reveal a structure-activity relationship of the bis-pyrazole class of molecules with -C-C-, -C-N- and -C-O- linkers, and their evaluation as inhibitors of phagocytosis of antibody-opsonized human RBCs as potential therapeutics for ITP. We have uncovered three potential candidates, 37, 47 and 50, all carrying a different linker connecting the two pyrazole moieties. Among these compounds, hydroxypyrazole derivative 50 is the most potent compound with an IC50 of 14 ± 9 μM for inhibiting the phagocytosis of antibody-opsonized human RBCs by macrophages. None of the compounds exhibited significant potential to induce apoptosis in peripheral blood mononuclear cells (PBMCs). Current study has revealed specific functional features, such as up to 2-atom spacer arm and alkyl substitution at one of the N1 positions of the bivalent pyrazole core to be important for the inhibitory activity.

PYRAZOLE DERIVATIVES AND THEIR USES THEREOF

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

Design, synthesis, and pharmacological profile of novel fused pyrazolo[4,3-d]pyridine and pyrazolo[3,4-b][1,8]naphthyridine isosteres: A new class of potent and selective acetylcholinesterase inhibitors

A new family of tacrine (THA) analogues (7-9, 12), containing the azaheterocyclic pyrazolo-[4,3-d]pyridine or pyrazolo[3,4-b] [1,8]naphthyridine systems as isosteres of the quinoline ring of THA, has been synthesized. The compounds were tested in rat brai

Synthesis and analgesic properties of new 5-thioaryl pyrazole derivatives.

A new series 5-thio aryl pyrazole derivatives were proposed aiming analgesic activity. In this work, 8 new compounds of this class were synthesized using usual synthetic methodology, having as key intermediate the 3-methyl-4-nitro-5-chloropyrazole-1-pheny

Hetarylpyrazoles. IV. (1) Synthesis and Reactions of 1,5'-Bipyrazoles

A number of 1,5'-bipyrazoles were obtained from the condensation of pyrazol-5-ylhydrazine and 1,3-dicarbonyl compounds.Electrophilic substitution reactions of these 1,5'-bipyrazoles occur at the four position of the pyrazole ring.

4-Nitropyrazoles

Covers a method of inducing abscission of fruit by applying a chemical composition containing an effective amount of a 4-nitropyrazole as the active ingredient in an agronomically acceptable carrier. Also covers certain 4-nitropyrazoles.